Follow us on
Search News Archives
Conferences | Events
Monthly Newsletter
Lab Bulletin Media Partners

Optibrium Introduces StarDrop 6.5

publication date: Jul 11, 2018
 | 
author/source: Optibrium Ltd

OptibriumOptibrium™, a developer of software for drug discovery, has announced the launch of version 6.5 of StarDrop™ that provides a complete platform for small molecule design, optimisation and data analysis.

The latest release introduces WhichP450, a new feature in StarDrop’s P450 metabolism module that predicts which human Cytochrome P450 enzymes are the major metabolising isoforms for a novel compound. Understanding how a compound is metabolised enables identification and analysis of its potential metabolites, and guides the design of molecules with a reduced risk of drug-drug interactions or variations in exposure across the patient population.

Also included in the latest version of StarDrop is novel R-group clipping functionality that quickly transforms chemical building blocks into their corresponding substituents for enumeration of virtual libraries and the exploration of new compound ideas. Associated data, such as inventory and cost for each building block, are linked with the enumerated compounds to facilitate ordering for synthesis of the best compounds.

The new features are introduced in parallel with an enhanced data visualisation environment offering more chart types, additional formatting options and a streamlined user interface, enabling publication-quality graphics to be created in just a few clicks. This is teamed with a new ‘dashboard’ capability, combining multiple interactive plots in a configurable project view, enabling scientists, team leaders and managers to track the progress of a project at a glance.

Dr Matthew Segall, Optibrium’s CEO, commented: “We continue to invest in leading-edge research to bring the latest modelling approaches to our users in an intuitive interface. StarDrop’s enhanced capabilities ensure that scientists can quickly understand structure-activity relationships, identify potential liabilities and design new compounds with the highest chance of success. This leads to better decisions and shorter project timelines.”


more news from Optibrium



If you have not logged into the website then please enter your details below.



 

Popular this month


Win an INTEGRA VOYAGER adjustable tip spacing pipette


Leeds Teaching Hospitals NHS Trust Pathology Lab to digitally scan 100% of slides


Thermo Fisher Scientific Announces Collaboration to Simplify Analysis of Complex Therapeutic Proteins


FreeLIMS.org launches a free, Laboratory Information Management System


Mira P for the pharmaceutical industry: Instant onsite verification of raw materials


Take your microwell plate pipetting to the next level!


World’s first high throughput microplate reader for circular dichroism


Eppendorf Presents First Internally Developed CO2 Incubator


Three benefits of hiring freelance Scientists


 

Can't find what you are looking for?


Search by company or by product


Company Name:

Product:





Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd